One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood.v120.21.202.202
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 16, 2012 |
 Citations: 30 |
Affiliation: Dana-Farber Cancer Institute, Harvard University, Mount Sinai Medical Center, Hôtel-Dieu de Paris, University of Chicago Medical Center, Heidelberg University, Washington University in St. Louis, Queen Elizabeth II Health Sciences Centre, Princess Margaret Cancer Centre, Centre Hospitalier Universitaire de Tours, Karmanos Cancer Institute, Abbott (United States), Bristol-Myers Squibb (United States), Sab Biotherapeutics (United States), Emory University
A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
